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Cardiovascular disease (CVD) is the leading cause of death in India, accounting for 28% of mortality. The average age of onset
of CVD is younger (below 55 years) among Indians than in other populations. This may be due to bad lifestyle, genetic factors,
or both. Hypertension, smoking, diabetes, and physical inactivity have been identiﬁed as modiﬁable risk factors for heart disease.
Hypercholesterolemia is the most common and treatable cause of heart disease. Genetic factors that lead to hypercholesterolemia
have not been fully studied in India. Familial Hypercholesterolemia results from mutations in the LDL receptor, ApoB, PCSK9,
and ApoE genes. There is an urgent need to screen subjects with premature CAD and their relatives in India for the presence of
FH, identify the mutations that lead to high cholesterol, and carry out cascade screening in the at-risk relatives. Those harbouring
mutations in the above genes can be treated to lower the cholesterol levels, prevent early CVD, and avoid death. A programme
based on these lines has been initiated in Delhi.
1.Introduction
Cardiovascular disease (CVD) is the leading cause of death
in India, accounting for 28% of mortality [1]. Deaths from
CVD have increased from 2,266,000 in 1990 to 2,669,100
in 2004, which is a 17.8% increase in less than two decades
[2]. Prevalence of CVD in the urban Indian population is
between6.5to13.2%andintheruralpopulationbetween1.6
to 7.4%. The prevalence in the rural areas is growing rapidly
possibly due to changing life styles [3].
The average age of onset of CVD is younger (below
55 years) among Indians than in other populations around
the world [4]. The case fatality rate for coronary heart
disease and other CVDs is higher in India than in the
developed countries. This is because eﬀective mechanisms
for management and control of CVD are not been fully
established and also due to cost of interventions. The heavy
burdenofCVDinIndiansisgenerallyconsideredtobedueto
increasedincidenceofmetabolicsyndromeandanunhealthy
lifestyle.Investigationsofthegeneticcausesforthisincreased
trend have been largely unexplored and the contribution of
Familial Hypercholesterolemia (FH) is unknown.
TheFraminghamHeartStudy(FHS)wasstartedin1950s
when there was growing burden of CVD in the United
States. It led to the recognition of risk factors for CVD
such as smoking, high blood pressure, an abnormal lipid
proﬁle,obesity,diabetes,physicalinactivity,andpsychosocial
factors. This has been shown to be true in all ethnic groups
[5].AsianIndianshavebeenshowntomanifestCVDatlower
levels of these risk factors, as compared to other populations.
Epidemiological studies have been conducted in India
to determine the prevalence and age-speciﬁc trends in
cardiovascular risk factors among adolescents and young
Asian Indians. Major risk factors identiﬁed were smoking
or tobacco use, obesity, hypertension, dysglycemia, and
dyslipidemia. It was observed that the prevalence of multiple
cardiovascular risk factors was low in adolescents, but rapid2 Cardiology Research and Practice
escalation of these risk factors occurred by the age 30–39
years [6].
Arora and Trehan [7] investigated 3020 cases of Indians
having Coronary Artery Bypass Graft (CABG) for three or
more vessel disease in comparison with those having two or
less vessel disease. Risk factors diﬀered in the cases with early
as compared with those having late onset of CAD. Cigarette
smoking and positive family history of CAD was observed
more frequently in those with early onset of the disease,
whereas hypertension and diabetes mellitus occurred more
frequently in those with late onset of disease.
Goel and colleagues [8] documented that in Indians
the risk factors for CAD occur at much lower levels of
totalcholesterolandlow-densitylipoproteincholesterolthan
other populations. High triglyceride and low high-density
lipoprotein levels were observed in the Indian subjects.
Younger patients had a more atherogenic lipid proﬁle than
the older subgroup with CAD. Smoking and family history
of premature CAD were the most common associated risk
factors.
High cholesterol level, the major modiﬁable risk factor
f o rh e a r td i s e a s e ,h a sb o t ha ne n v i r o n m e n t a la sw e l la sa
genetic component. Premature CAD in the Indian pop-
ulation might be due to an unhealthy lifestyle alone or
due to genetic factors in combination with an unhealthy
lifestyle. The genetic component has been largely ignored
in India although it has the highest number of deaths due
to heart disease. It would be interesting to determine what
fraction of deaths due to CVD are due to genetic factors
especially FH. Many countries in the west have introduced
MEDPED (Make Early Diagnosis to Prevent Early Death)
programs. An index case with FH is identiﬁed, and the
responsible molecular mutation is determined. Then using
a combination of cholesterol levels and mutation studies, the
extended family members are screened. The programme has
been highly successful in reducing mortality due to CVD in
these subjects [9].
Reports are available from the Indian subcontinent of
cases with Homozygous FH that have been identiﬁed on der-
matological and cardiological features [10–12]. In all these
cases, the patients had a very characteristic distribution of
planar xanthomas in interdigital spaces of ﬁngers along with
tendinous and some tuberous xanthomas at other places. It
was observed that most of these patients had a family history
of xanthomas, premature deaths, and deranged plasma
cholesterol levels in siblings or the parents. The treatment
options available are lipid lowering drugs, LDL apheresis,
and liver transplantation [13–15]. Genetic characterization
in such families would enable early diagnosis and provision
of therapy at a younger age. Guidelines have been developed
in UK for diagnosis and treatment of patients of FH and
cascade testing among family members [16].
Hypercholesterolemia (monogenic and multifactorial)
aﬀects 1 in 20 subjects in the general population. On
the other hand, frequency of FH is 1 in 500 for het-
erozygotes. Homozygotes are rare with a frequency of 1
in a million. FH is characterized by isolated elevation of
plasma low-density lipoprotein cholesterol and is associated
with high risk of premature cardiovascular disease. The
aﬀected families can be segregated in three clear groups on
the basis of their plasma LDL cholesterol concentrations:
presumed homozygotes with levels four times higher than
in normal individuals (>800mg/dL), heterozygotes with
levels two times higher than the normal (200–800mg/dL),
and unaﬀected individuals (100mg/dL). This is due to the
gene dosage eﬀect [17]. It is estimated that there are about
10,000,000 people with FH worldwide [18]. Of these aﬀected
subjects, less than 10% are treated with LDL-lowering drugs.
Ifundiagnosedanduntreated,thecumulativeriskofCADby
age 60 years is more than 60% among men and 30% among
women with heterozygous FH [19]. This risk ratio could be
much higher in Indians due to the early occurrence of CAD.
2. The GeneticEquationinFH
FamilialHypercholesterolemiaresultsfromdefectsinhepatic
uptake and degradation of LDL via the LDL-receptor
pathway. The high-density lipoprotein cholesterol levels are
seen to be in the normal range or low in patients with
FH. The defects are generally caused by loss of function
mutations in the LDL receptor gene, by mutations in gene
encoding apolipoprotein B, or by gain of function mutations
in PCSK9 gene.
2.1. LDL Receptor Gene. In 1985, Brown and Goldstein [20]
discovered the LDL receptor, a cell surface glycoprotein that
binds apolipoprotein B on the LDL particle as a part of the
process of receptor mediated endocytosis. The human LDLR
receptor cDNA and gene were cloned and characterized
in 1984 and 1985, respectively [21]. LDL receptor gene is
located on the distal short arm of chromosome 19, in the
region p13.1-p13.3. LDLR gene spans 45kb and comprises
of 18 exons and 17 introns. The cellular defects of LDL-
receptor function are classiﬁed into ﬁve groups: defects
in ligand binding, transport, internalization, recycling, and
null alleles which are the receptor negative mutations. The
ﬁrst molecular characterization of LDL receptor mutation
was reported in 1985 by Lehrman et al. [22]. More than
900 mutations in the LDLR have been reported since
its discovery [23]. Various mutations found include point
mutations, large rearrangements, premature stop codons,
single amino acid substitutions and insertions [24–26]. Not
much work has been done in the ﬁeld of molecular genetic
characterization of FH in the Indian population. A study on
Indians in South Africa found mutations in exons 3, 4, 9,
a n d1 4o fL D L Rg e n e .T h em u t a t i o n sm a j o r l yo c c u r r e di n
the CpG rich regions of the gene making it a mutational
hotspot in South African Indians [27]. Unrelated families
haddiﬀerentmutations.Ashavaidetal.inastudyinMumbai
identiﬁed four previously known mutations and two novel
insertion mutations in LDLR gene in Indian subjects [28].
2.2.ApoB. Somepatientswithhypercholesterolemiahaveno
defect in LDL receptor, but have defective clearance of LDL
due to mutations in ApoB gene. In such patients, cholesterol
concentrations in plasma can vary from those found in
heterozygous FH to only modest hypercholesterolemia [29].Cardiology Research and Practice 3
The defect lies in inability of the LDL to bind to LDLR
receptor due to defective ApoB, the protein moiety of LDL
[30]. The defect is known as Familial Defective Apolipopro-
tein B-100 (FDB). Mutations are found only in the LDL
binding domain of ApoB, which consists of exon 26 and
27 of ApoB gene. In a study conducted in 40 subjects
with clinical features of FH in India, none of the patients
or controls showed a mutation in exon 26 of ApoB. This
suggests that common mutations in ApoB are not associated
with hypercholesterolemia among Indians [31].However the
possibility of other unknown mutations and polymorphisms
at the ApoB locus cannot be ruled out.
2.3. PCSK9. Another locus causing autosomal dominant
hypercholesterolemia was identiﬁed to be a gene on chro-
mosome 1-Proprotein Convertase Subtilisin/Kexin type IX
(PCSK9) [32]. This gene encodes for a protein of 694
amino acids belonging to a family of proprotein convertase
subtilase. PCSK9 is secreted by hepatocytes and appears to
downregulate the density of functional LDL receptors in
hepatocytes by promoting endosomal degradation rather
than recycling of the receptor on the surface [33]. Hyper-
cholesterolemia is caused by gain-of-function mutations in
the PCSK9 gene [34]. Since its discovery, various missense
mutations in PCSK9 have been shown to cosegregate with
severe hypercholesterolemia in many families in several
countries. It was observed that ApoE genotypes exerted their
respective eﬀects on LDL cholesterol in an additive manner
to that of the PCSK9 variants [35].
2.4. ApoE. It is a key protein in the modulation of
metabolism of highly atherogenic ApoB containing lipopro-
teins. ApoE is polymorphic in nature and three common
alleles, that is, ε4, ε3, and ε2 code for three major isoforms,
that is, ApoE4, E3, and E2. Six diﬀerent ApoE phenotypes:
E3/3, E4/4, E2/2, E4/3, E3/2, and E4/2 occur in the general
population with varying frequencies. It has been estimated
that ApoE polymorphisms may account for 2–16% of the
variability of LDL cholesterol levels [36]. In Asian Indians,
these allele frequencies observed were 0.031–0.094 for ε2,
0.803–0.968 for ε3, and 0.000–0.133 for ε4[ 37]. Frequency
of ApoE ε3 allele was found to be high (0.913) in people
of north India [38]. In another study on Asian Indians,
individuals with at least one ε4a l l e l ew e r ec o n s i d e r e d
to be at risk to develop premature myocardial infarction,
independent of other conventional risk factors [39].
3. Conclusions
Special eﬀorts are required to identify individuals with FH
in India as they are at high risk of premature coronary heart
disease. The condition is seriously underdiagnosed and the
diagnosis is often made too late, restricting the beneﬁts of
the treatments available. Since this condition is genetically
determined, families must become the focus of attention.
Cascade testing can identify more individuals with FH who
will beneﬁt from early treatment, result in a near-normal life
expectancy. The innovative use of DNA testing allied with
cholesterol assay will help to ensure that children, young
people, and adults with this condition are identiﬁed and
oﬀered timely advice and treatment. A cost-eﬀective method
is being developed to screen for mutations in families with
cases having premature CAD. This will help to establish a
programinIndiasimilartotheMEDPEDprogram.Withthis
initiative many lives will be saved from premature CAD and
early death.
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